Lower-dose duloxetine with alpha-lipoic acid for painful diabetic nerve damage
Compares low-dose duloxetine plus alpha-lipoic acid with standard duloxetine in adults with painful diabetic neuropathy.
Key facts
- Who runs it
- Bangladesh Medical University
- Where
- Bangladesh1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Efficacy and Safety of Low-Dose Duloxetine Plus Alpha-Lipoic Acid Versus Standard-Dose Duloxetine in Painful Diabetic Peripheral Neuropathy
- Status
- Not yet recruiting
- People taking part
- 170 people, planned
- Started
- 25 Aug 2026
- Expected to end
- Aug 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Duloxetine
- Alpha-Lipoic Acid
- Record updated
- 26 August 2026
Who can take part
The trial is looking for adults with diabetes who have painful nerve damage in the feet or hands (diabetic peripheral neuropathy). It compares low-dose duloxetine plus alpha-lipoic acid with standard-dose duloxetine.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Diabetic peripheral neuropathy with a Toronto Clinical Neuropathy Score (TCNS) of 6 or more. Painful neuropathy with a LANSS Pain Scale score of 12 or more. Nerve symptoms for 3 months or longer. Pain score (NRS) of 4 or more at the start.
- Earlier treatment
- No antidepressants, antiepileptic drugs, sedatives, antipsychotic drugs or opioids in the past 4 weeks.
- Main reasons for not taking part
- Pain from other causes, such as poor blood flow in the legs, arthritis, phantom limb pain or nerve root pain.
- Other causes of nerve damage, such as known vitamin B12 deficiency, low thyroid, chronic alcohol use, chemotherapy or HIV infection.
- Chronic kidney disease stage 4 or higher, or chronic liver disease or ALT >3 times the upper normal limit.
- Pregnancy, breastfeeding, or planning pregnancy during the study.
- Major depression, memory or thinking problems (MMSE <24), active cancer, or allergy to duloxetine or alpha-lipoic acid.
Show the full registry criteria (14)Hide the full registry criteria
Who can take part
- Age ≥18 years
- Diagnosed case of diabetes mellitus
- Diabetic peripheral neuropathy diagnosed clinically according to the Toronto Clinical Neuropathy Score (TCNS) criteria with a TCNS score ≥6, with painful neuropathy confirmed using the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) Pain Scale with a score ≥12
- Duration of neuropathic symptoms ≥3 months
- Baseline Numerical Rating Scale (NRS) pain score ≥4
- Willingness to participate in the study and provide written informed consent
Who cannot take part
- Use of antidepressants, antiepileptic drugs, sedatives, antipsychotic drugs, or opioids within the preceding 4 weeks
- Pain attributable to causes other than diabetic peripheral neuropathy, such as peripheral arterial disease (ischaemic pain), osteoarthritis, inflammatory arthritis, phantom limb pain, radiculopathy, or other chronic pain disorders
- Known vitamin B12 deficiency, hypothyroidism, chronic alcohol use, hereditary neuropathy, chemotherapy-induced neuropathy, HIV infection, or connective tissue disease
- Chronic kidney disease (CKD) stage ≥4
- Known hypersensitivity or contraindication to duloxetine or alpha-lipoic acid
- Major depressive disorder as assessed by the Patient Health Questionnaire-9 (PHQ-9), cognitive impairment (MMSE <24), active malignancy, or any serious medical condition that, in the opinion of the investigator, may interfere with study participation, treatment adherence, or outcome assessment
- Chronic liver disease or significant hepatic impairment (ALT >3 times the upper normal limit)
- Pregnancy or lactation, or women planning pregnancy during the study period
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Painful diabetic peripheral neuropathy
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study will evaluate the efficacy and safety of low-dose duloxetine combined with alpha-lipoic acid compared with standard-dose duloxetine in adults with painful diabetic peripheral neuropathy. In this assessor-blinded, randomized, parallel-arm, non-inferiority trial, participants will be assigned in a 1:1 ratio to receive either duloxetine 30 mg once daily plus alpha-lipoic acid 600 mg once daily or duloxetine 60 mg once daily. The primary outcome will be the change in pain intensity measured by the Numerical Rating Scale from baseline to Week 9. Secondary outcomes will include changes in pain intensity at Week 5, Patient Global Impression of Change at Weeks 5 and 9, the proportion of participants achieving at least a 30% reduction in pain intensity, adverse effects, treatment tolerability and treatment compliance.
The 2 groups in the trial
- Duloxetine 30 mg + Alpha-Lipoic Acid 600 mgTreatment being tested
Duloxetine 30 mg will be administered orally once daily throughout the treatment period. Alpha-lipoic acid 600 mg will be administered orally once daily from Week 2 through Week 9.
Treatment: Duloxetine and Alpha-Lipoic Acid
- Duloxetine 60 mgExisting treatment, for comparison
Duloxetine 30 mg will be administered orally once daily during Week 1, followed by duloxetine 60 mg orally once daily from Week 2 through Week 9.
Treatment: Duloxetine
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of Low-Dose Duloxetine Plus Alpha-Lipoic Acid Versus Standard-Dose Duloxetine in Painful Diabetic Peripheral Neuropathy: An Assessor-Blinded Randomized Controlled Non-Inferiority Trial
- Plain-language title
- Lower-dose duloxetine with alpha-lipoic acid for painful diabetic nerve damageGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07785544, who can take part
- Record updated
- 26 August 2026